DrugPatentWatch Database Preview

TASIGNA Drug Profile

« Back to Dashboard

Which patents cover Tasigna, and when can generic versions of Tasigna launch?

Tasigna is a drug marketed by Novartis and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and seventy patent family members in fifty-one countries.

The generic ingredient in TASIGNA is nilotinib hydrochloride. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nilotinib hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Tasigna

Tasigna was eligible for patent challenges on October 29^th, 2011.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 7^th, 2032. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Summary for TASIGNA

International Patents:	270
US Patents:	7
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	113
Clinical Trials:	57
Patent Applications:	4,597
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for TASIGNA
DailyMed Link:	TASIGNA at DailyMed

See drug prices for TASIGNA

Generic Entry Opportunity Date for TASIGNA

NDA:

022068

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TASIGNA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institutes of Health (NIH)	Phase 2
Commissariat A L'energie Atomique	Phase 3
Plateforme labellisée Inca – Institut Bergonié, Bordeaux	Phase 3

See all TASIGNA clinical trials

Pharmacology for TASIGNA

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors

Synonyms for TASIGNA

139316-EP2270008A1

139316-EP2292617A1

3gp0

4-Methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-(5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl)benzamide

4-Methyl-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide

4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide

4-Methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide

4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-{(4-(pyridin-3-yl)pyrimidin-2-yl)amino}benzamide

4-Methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide

4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide

4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide

4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide

4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide

4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridyl)pyrimidin-2-yl]amino]benzamide

49312-EP2270008A1

49312-EP2292617A1

49312-EP2305667A2

49312-EP2311840A1

571N100

641571-10-0

78680-EP2305667A2

AB0007991

AB01273978_03

AB01273978-01

AB01273978-02

ABP000478

AC-647

AC1LD8U3

AKOS005063561

AM20090651

AMN 107

AMN 107; Tasigna

AMN-107

AMN107

AN-5308

ANW-41982

AOB87115

API0003575

AS-16214

AX8144766

BC224537

BCP01367

BCP9000989

BCPP000149

BDBM50237710

Benzamide, 4-methyl-N-((3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-

Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-(4-(3-pyridinyl)-2-pyrimidinyl)amino)-

benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-

Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- (9CI)

BR-59889

BRD-K81528515-001-04-7

C28H22F3N7O

cc-353

CHEBI:52172

CHEMBL255863

CS-0102

CTK8B3214

D08953

DB04868

DTXSID5042663

EC 700-544-5

EN002707

F41401512X

FC0027

FT-0654026

GP5854

GTPL5697

HHZIURLSWUIHRB-UHFFFAOYSA-N

HMS3244A13

HMS3244A14

HMS3244B13

HMS3654M07

HSDB 7842

HY-10159

I01-1225

KS-00000GT9

MFCD09833716

MLS003915611

MLS006010160

MolPort-003-987-089

N-(3-(3-(1H-Imidazolyl)propoxy)phenyl)-4-methyl-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)benzamide

N-8207

NCGC00183285-01

NCGC00183285-03

NCGC00183285-04

NCGC00183285-09

Nilotinib

Nilotinib (AMN-107)

Nilotinib (USAN/INN)

Nilotinib [USAN:INN:BAN]

Nilotinib & its intermediates

Nilotinib, AMN107, Tasigna

Nilotinib,AMN107,Tasigna;4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

Nilotinib;

Nilotinib(AMN-107)

Nilotinib/

nilotinibum

NSC-747599

NSC747599

P111010

PubChem18272

Q-101348

QCR-112

RS0102

RTX-011143

S-6060

s1033

SB17315

SC-19640

SCHEMBL7901

SMR002544680

SR-01000931150

SR-01000931150-2

ST2413627

SW218083-2

SYN1057

Tasigna (Novartis)

TL8004531

UNII-F41401512X

V0705

ZINC6716957

Paragraph IV (Patent) Challenges for TASIGNA

Tradename	Dosage	Ingredient	NDA	Submissiondate
TASIGNA	CAPSULE;ORAL	nilotinib hydrochloride	022068	2019-10-17
TASIGNA	CAPSULE;ORAL	nilotinib hydrochloride	022068	2013-11-08

US Patents and Regulatory Information for TASIGNA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007		RX	Yes	Yes
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007		RX	Yes	Yes					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007		RX	Yes	Yes					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007		RX	Yes	Yes					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018		RX	Yes	No					Y

International Patents for TASIGNA

Country	Patent Number	Estimated Expiration
Cyprus	1113076
Guatemala	200600316
Norway	341313
South Korea	20140047737
Tunisia	SN08028